TY - JOUR
T1 - Sister chromatid exchanges in the lymphocytes of tuberculosis patients receiving short-term chemotherapy
AU - Gopal Rao, V. V.N.
AU - Venkatarama Gupta, E. V.
AU - Thomas, I. M.
N1 - Funding Information:
Part of this work was financially supported by the Indian Council of Medical Research, New Delhi, and the authors gratefully acknowledge the same. The help rendered by the staff of the Lady Wellingdon State Tuberculosis Centre, in collecting the patients is also gratefully acknowledged.
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1990/9
Y1 - 1990/9
N2 - The frequency of sister chromatid exchanges was estimated in tuberculosis patients undergoing three different short term chemotherapy regimens (2SHRZ, 2HRZ and 2H2R2Z2), to evaluate the possible genetic damage caused by anti-Tuberculous drugs. Of the three combinations studied, two combinations (2SHRZ and 2HRZ), which were administered daily, enhanced the frequency of sister chromatid exchanges significantly (p < 0.05), while the third bi-weekly combination 2H2R2Z2), did not show any significant enhancement in the frequency of sister chromatid exchanges. These results are of importance in the treatment of tuberculosis, and indicate the need to select a drug combination that is equally efficient in the control of disease and at the same time less harmful to the genome of the patient.
AB - The frequency of sister chromatid exchanges was estimated in tuberculosis patients undergoing three different short term chemotherapy regimens (2SHRZ, 2HRZ and 2H2R2Z2), to evaluate the possible genetic damage caused by anti-Tuberculous drugs. Of the three combinations studied, two combinations (2SHRZ and 2HRZ), which were administered daily, enhanced the frequency of sister chromatid exchanges significantly (p < 0.05), while the third bi-weekly combination 2H2R2Z2), did not show any significant enhancement in the frequency of sister chromatid exchanges. These results are of importance in the treatment of tuberculosis, and indicate the need to select a drug combination that is equally efficient in the control of disease and at the same time less harmful to the genome of the patient.
UR - http://www.scopus.com/inward/record.url?scp=0025072608&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025072608&partnerID=8YFLogxK
U2 - 10.1016/0041-3879(90)90071-F
DO - 10.1016/0041-3879(90)90071-F
M3 - Article
C2 - 2238122
AN - SCOPUS:0025072608
SN - 0041-3879
VL - 71
SP - 173
EP - 176
JO - Tubercle
JF - Tubercle
IS - 3
ER -